Plain-English translation of NCT06276491 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This trial is testing an investigational medication called in people with advanced cancers including ovarian, endometrial, and germ cell tumors. The study aims to find out if this medication is safe and well tolerated, what the best dose is, and whether it helps shrink or slow tumor growth. The medication is given as an intravenous (IV) or subcutaneous (under-the-skin) injection.
Many patients with these types of advanced cancers have limited treatment options, especially if their cancer has come back after previous treatment. This medication targets a specific protein (CLDN6) found on certain cancer cells, and this trial is exploring whether this new approach could offer hope to patients who need new options.
You likely qualify if…
You likely don't qualify if…
You would receive the medication either as an IV infusion or an injection under the skin at regular clinic visits. The study begins with a dose escalation phase, where researchers gradually increase doses in small groups of patients to find the safest level, followed by an expansion phase where more patients receive the dose deemed safe. You would have blood tests, imaging scans, and physical exams to monitor how well the medication is working and to watch for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States